国产多西他赛为主的联合化疗治疗转移性乳腺癌  

Domestic Docetaxel-based Combination Chemotherapy in Treatment of Metastatic Breast Cancer

作　　者：张珺[1] 梁亚军 胡长耀[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院综合科,武汉430030 [2]武汉市商业职工医院内一科

出　　处：《肿瘤防治研究》2007年第10期780-782,共3页Cancer Research on Prevention and Treatment

摘　　要：目的观察国产多西他赛为主的联合化疗治疗转移性乳腺癌的疗效、毒副反应和临床受益反应(Clinical benefit response,CBR),并以进口多西他赛作对照。方法A组30例转移性乳腺癌患者,既往未采用蒽环类药物治疗的14例采用国产多西他赛联合阿霉素治疗(A1组),既往蒽环类药物治疗失败的16例采用国产多西他赛联合卡培他滨治疗(A2组);B组25例转移性乳腺癌患者作对照,其中未采用蒽环类药物治疗的11例采用进口多西他赛联合阿霉素治疗(B1组),既往蒽环类药物治疗失败的14例采用进口多西他赛联合卡培他滨治疗(B2组);3周为1个周期,2周期评价疗效,记录毒副反应。结果A组有效率(CR+PR)66.7%,肿瘤控制率(CR+PR+SD)93.3%。毒副反应主要为骨髓抑制和脱发,可耐受,无治疗相关性死亡。CBR评价有效者73.3%;B组有效率68%,肿瘤控制率92%。毒副反应与A组相似。CBR评价有效者72%。结论国产多西他赛为主的联合化疗治疗转移性乳腺癌有较好的疗效,毒副反应可耐受,临床受益反应良好,与进口多西他赛的疗效和不良反应相似。Objective With taxotere as a control, to evaluate the efficacy, toxicity and CBR of domestic do- cetaxel-based combination chemotherapy in the treatment of metastatic breast cancer. Methods Fourteen metastatic breast cancer patients without anthracycline-pretreated were treated with docetaxel and doxo- rubicin（A1）and sixteen metastatic breast cancer patients with anthracycline-pretreated were treated with docetaxel and capecitabine（A2）. Eleven metastatic breast cancer patients without anthracycline-pretreated were treated with taxotere and doxorubicin （B1） and fourteen metastatic breast cancer patients with an- thracycline-pretreated were treated with taxotere and capecitabine（B2）. Every 3 weeks a cycle. Efficacy, toxicity and CBR were recorded in every 2 cycles. Results Fifty- five patients were evaluated. The re- sponse rate was 66. 7% and 68%. The tumor control rate was 93.3% and 92%. The main toxicities were bone marrow suppression and alopecia, and were tolerable. The CBR was 73.3% and 72%. There was no significant difference between treated group and control group. Conclusion Domestic docetaxel-based combination chemotherapy is effective for metastatic breast cancer. It is well-tolerated and well-clinical benefit responsed.

关 键 词：多西他赛 乳腺癌 化学治疗 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]